Lupin's Aurangabad Facility Receives EIR from USFDA

03 Apr 2020 Evaluate
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad, India facility. The inspection for the facility was carried out by the USFDA between February 10, 2020 and February 14, 2020 and concluded with no observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×